FDA approves AZ Imfinzi in new lung cancer use
AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer, and it stopped a trial of its Farxiga after showing “overwhelming efficacy” in chronic kidney disease.
Imfinzi’s approval in untreated extensive-stage small cell lung cancer (ES-SCLC), in combination with etoposide or either carboplatin or cisplatin means that the immunotherapy will take on Roche’s Tecentriq (atezolizumab).
Tecentriq was approved by the FDA in ES-SCLC last year, but AZ says it may have an advantage as Imfinzi’s label is broader, giving a choice of chemotherapy options.
Imfinzi’s approval by the FDA is based on the phase 3 CASPIAN trial showing Imfinzi combined with standard platinum chemotherapy significantly improved overall survival versus chemotherapy alone.
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.
Merck & Co’s rival immunotherapy Keytruda (pembrolizumab) in January failed to improve overall survival in this indication.
Farxiga trial stopped early
At the same time AZ reported that the phase 3 DAPA-CKD of Farxiga (dapagliflozin) in patients with chronic kidney disease (CKD) with and without type 2 diabetes was stopped early after “overwhelming efficacy”.
Results set up a showdown with Eli Lilly/Boehringer Ingelheim’s rival SGLT-2 drug Jardiance (empagliflozin), which the FDA has agreed to fast track through the clinical development process in CKD.
The DAPA-CKD trial was stopped early following a recommendation from the trial’s independent Data Monitoring Committee after a routine interim assessment.
Data collected so far show Farxiga’s displaying benefits earlier than originally anticipated and AZ will begin closing the trial.
The primary endpoint of DAPA-CKD is a composite of worsening renal function or death, and onset of end-stage kidney disease or cardiovascular or renal death in patients with CKD, irrespective of the presence of type 2 diabetes.
AZ is building a franchise in metabolic diseases around Farxiga, which is already FDA approved to reduce hospitalisation for heart failure in patients with type 2 diabetes, and to control blood sugar levels in type 2 diabetes patients.
The FDA gave Farxiga a Fast Track designation in CKD, allowing for a fast six-month review of trial results.
It is also benefiting from the six-month Priority Review with the FDA for patients with heart failure.
Other regulators including the European Medicines Agency are also reviewing clinical trial results in heart failure.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.